Equities

Biogened SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
BGD:WSE

Biogened SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (PLN)21.00
  • Today's Change0.20 / 0.96%
  • Shares traded110.00
  • 1 Year change-22.22%
  • Beta0.3657
Data delayed at least 15 minutes, as of Feb 12 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Biogened SA is a Poland-based company active in the healthcare sector. The Company is engaged in production and distribution of generic pharmaceuticals in psychiatry, neurology and oncology, as well as development, production and distribution of dermocosmetics and diet supplements. The Company’s product portfolio includes: Polmantis and SST Salvia Stimulating Tablets (pharmaceuticals), Dermedic, Ellexir, Herba Botanic and Novoscabin (dermocosmetics), and Fibers, Prolady, Futimal and Dermedic Caps (diet supplemenst). As of March 31, 2012, Life Science Technologies NV held an 80.92% stake in the capital.

  • Revenue in PLN (TTM)115.12m
  • Net income in PLN5.73m
  • Incorporated2007
  • Employees223.00
  • Location
    Biogened SAul. Pojezierska 99LODZ 91-342PolandPOL
  • Phone+48 426513152
  • Fax+48 426511243
  • Websitehttps://www.biogened.pl/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
BLIS Technologies Ltd30.68m2.20m49.27m39.0023.291.7014.991.610.00070.00070.01020.011.02--11.80367,282.107.31-3.448.17-3.97----7.18-3.726.3230.350.0396--9.703.5129.72-12.1623.66--
Krebs Biochemicals And Industries Ltd9.02m-8.96m49.53m202.00------5.49-10.60-10.6010.68-74.60------1,139,753.00---16.90---26.5696.2720.39-99.30-55.630.0359-2.423.65---14.105.33-36.55---17.65--
BIOGENED SA115.12m5.73m51.58m223.008.991.185.640.44812.332.3346.8717.841.331.745.43--5.634.167.436.0265.2568.274.243.961.403.830.3443--16.0918.9314.2235.568.39--
Phapros Tbk PT180.66m-44.23m52.12m1.26k--0.6336--0.2885-249.48-249.481,019.16463.990.5472.361.88649,537,700.00-13.71-2.15-21.02-4.1141.2648.61-25.06-3.951.02-2.190.6425---25.80-7.60-3,721.67---13.99--
Millennium Pharmacon Internationl Tbk PT843.07m3.55m52.70m1.18k14.860.83146.210.062513.1913.193,135.74235.762.176.554.683,382,665,000.000.91181.264.425.888.498.440.42080.53890.73631.360.738511.7316.457.51-48.8416.535.5314.87
Laboratorio Farmaceutico Erfo SpA32.37m1.63m53.83m47.0031.281.539.521.660.04540.04540.89640.92990.67343.867.09187,405.604.699.365.9911.5038.2747.806.9715.921.2119.410.1559--1.596.03-33.74-22.47----
Hoth Therapeutics Inc0.00-43.16m53.95m2.00--1.80-----1.06-1.060.000.54420.00----0.00-138.61-129.47-154.67-144.30-----------493.480.00-------4.37------
Sotac Pharmaceuticals Ltd31.90m3.41m54.12m67.0015.882.489.121.707.877.8773.6150.390.68182.862.6712,149,600.008.465.8116.2812.4737.2625.5912.404.690.97372.300.3854---6.5927.66124.25146.8911.66--
CASI Pharmaceuticals Inc95.26m-175.22m54.57m233.00------0.5728-2.98-2.981.62-1.850.60961.604.22115,218.90-107.02-36.27-277.91-51.9053.6857.36-175.56-124.010.236-13.27-----15.7747.19-45.62---55.67--
Data as of Feb 12 2026. Currency figures normalised to Biogened SA's reporting currency: Polish New Zloty PLN
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.